Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Get Free Report) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 4,130 shares, a decline of 36.9% from the August 31st total of 6,541 shares. Based on an average trading volume of 5,757 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.3% of the shares of the stock are short sold.
Hedge Funds Weigh In On Fidelity Disruptive Medicine ETF
An institutional investor recently bought a new stake in Fidelity Disruptive Medicine ETF stock. Citadel Advisors LLC acquired a new stake in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 9,896 shares of the company’s stock, valued at approximately $282,000. Citadel Advisors LLC owned about 0.62% of Fidelity Disruptive Medicine ETF as of its most recent SEC filing.
Fidelity Disruptive Medicine ETF Price Performance
Shares of NASDAQ FMED traded down $0.16 during midday trading on Thursday, reaching $32.23. 148 shares of the stock traded hands, compared to its average volume of 10,436. The company’s 50 day moving average is $30.91 and its 200 day moving average is $27.62. Fidelity Disruptive Medicine ETF has a one year low of $23.48 and a one year high of $32.89. The stock has a market capitalization of $51.57 million, a PE ratio of 41.33 and a beta of 0.77.
Fidelity Disruptive Medicine ETF Company Profile
The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.
See Also
- Five stocks we like better than Fidelity Disruptive Medicine ETF
- Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continue
- Anthropic’s IPO Could Put Amazon’s and Alphabet’s Paper Profits to the Test
- Microsoft’s AI Spending Didn’t Change—Wall Street’s View of It Did
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
Receive News & Ratings for Fidelity Disruptive Medicine ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fidelity Disruptive Medicine ETF and related companies with MarketBeat.com's FREE daily email newsletter.
